Are restricted mean survival time methods especially useful for noninferiority trials?

On the empirical choice of the time window for restricted mean survival time

(2020) Lu Tian et al.   BIOMETRICS

Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations

(2020) Anne Eaton et al.   Clinical Trials

Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes

(2020) David E. Kloecker et al.   ANNALS OF INTERNAL MEDICINE

Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?

(2020) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value

(2020) Bo Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to H. Uno et al and B. Huang et al

(2020) Boris Freidlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of survival distributions in clinical trials: A practical guidance

(2020) Xiaotian Chen et al.   Clinical Trials

Biodegradable-polymer stents versus durable-polymer stents

(2019) Lee-Jen Wei et al.   LANCET

Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development

(2019) David H. Manner et al.   AMERICAN HEART JOURNAL

Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies

(2019) Zachary R. McCaw et al.   CIRCULATION

Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

(2019) Boris Freidlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design of non-inferiority randomized trials using the difference in restricted mean survival times

(2018) Isabelle R Weir et al.   Clinical Trials

Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma

(2017) David Cheng et al.   JAMA Oncology

Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results

(2017) Dae Hyun Kim et al.   JAMA Cardiology

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

Statistical issues in the analysis of adverse events in time-to-event data

(2016) Arthur Allignol et al.   PHARMACEUTICAL STATISTICS

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

(2015) Hajime Uno et al.   ANNALS OF INTERNAL MEDICINE

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study

(2012) Lihui Zhao et al.   Clinical Trials